Coherus Oncology (CHRS) Net Cash Flow (2013 - 2026)

Coherus Oncology has disclosed Net Cash Flow across 14 years of filings, most recently posting $26.4 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at $26.4 million, up 160.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $32.8 million (up 118.48% YoY), and the FY2025 annual result was -$37.1 million, down 262.09% from the prior year.
• Net Cash Flow came in at $26.4 million for Q1 2026 at Coherus Oncology, up from -$14.5 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $156.9 million in Q1 2024 to a low of -$223.3 million in Q4 2022.
• The 5-year median for Net Cash Flow is -$14.5 million (2025), against an average of -$17.8 million.
• Peak annual rise in Net Cash Flow reached 430.96% in 2024, while the deepest fall reached 939.87% in 2024.
• Coherus Oncology's Net Cash Flow stood at -$223.3 million in 2022, then jumped by 110.14% to $22.6 million in 2023, then advanced by 25.03% to $28.3 million in 2024, then slumped by 151.15% to -$14.5 million in 2025, then jumped by 282.13% to $26.4 million in 2026.
• The last three Net Cash Flow figures came in at $26.4 million (Q1 2026), -$14.5 million (Q4 2025), and -$113.6 million (Q3 2025), per Business Quant data.